BRPI0410703A - compounds useful in the treatment of alzheimer's disease and formulations containing the same - Google Patents

compounds useful in the treatment of alzheimer's disease and formulations containing the same

Info

Publication number
BRPI0410703A
BRPI0410703A BRPI0410703-9A BRPI0410703A BRPI0410703A BR PI0410703 A BRPI0410703 A BR PI0410703A BR PI0410703 A BRPI0410703 A BR PI0410703A BR PI0410703 A BRPI0410703 A BR PI0410703A
Authority
BR
Brazil
Prior art keywords
alzheimer
disease
treatment
formulations containing
same
Prior art date
Application number
BRPI0410703-9A
Other languages
Portuguese (pt)
Inventor
Ezio Bombardelli
Gabriele Fontana
Luisella Verotta
Original Assignee
Indena Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Indena Spa filed Critical Indena Spa
Publication of BRPI0410703A publication Critical patent/BRPI0410703A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/587—Unsaturated compounds containing a keto groups being part of a ring
    • C07C49/703—Unsaturated compounds containing a keto groups being part of a ring containing hydroxy groups
    • C07C49/743—Unsaturated compounds containing a keto groups being part of a ring containing hydroxy groups having unsaturation outside the rings, e.g. humulones, lupulones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/587—Unsaturated compounds containing a keto groups being part of a ring
    • C07C49/703—Unsaturated compounds containing a keto groups being part of a ring containing hydroxy groups
    • C07C49/723—Unsaturated compounds containing a keto groups being part of a ring containing hydroxy groups polycyclic
    • C07C49/727—Unsaturated compounds containing a keto groups being part of a ring containing hydroxy groups polycyclic a keto group being part of a condensed ring system
    • C07C49/733—Unsaturated compounds containing a keto groups being part of a ring containing hydroxy groups polycyclic a keto group being part of a condensed ring system having two rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

"COMPOSTOS úTEIS NA TERAPIA DA DOENçA DE ALZHEIMER E FORMULAçõES CONTENDO OS MESMOS". A presente invenção refere-se a sais de floroglicinol com alcalóides inibidores de acetilcolinesterase e a métodos para preparação dos mesmos. Os ditos sais são de utilidade no tratamento de depressão e doença de Alzheimer, podendo ser administrados como formulações farmacêuticas convencionais ou como preparações transdermais de liberação controlada."USEFUL COMPOUNDS IN ALZHEIMER'S DISEASE THERAPY AND FORMULATIONS CONTAINING THEM". The present invention relates to floroglycinol salts with acetylcholinesterase inhibitor alkaloids and methods for their preparation. Said salts are useful in the treatment of depression and Alzheimer's disease and may be administered as conventional pharmaceutical formulations or as controlled release transdermal preparations.

BRPI0410703-9A 2003-05-30 2004-05-26 compounds useful in the treatment of alzheimer's disease and formulations containing the same BRPI0410703A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT001098A ITMI20031098A1 (en) 2003-05-30 2003-05-30 USEFUL COMPOUNDS IN ALZHEIMER DISEASE THERAPY AND FORMULATIONS CONTAINING THEM
PCT/EP2004/005644 WO2004106275A2 (en) 2003-05-30 2004-05-26 Compounds useful in the therapy of alzheimer’s disease and formulations containing them

Publications (1)

Publication Number Publication Date
BRPI0410703A true BRPI0410703A (en) 2006-06-13

Family

ID=30131121

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0410703-9A BRPI0410703A (en) 2003-05-30 2004-05-26 compounds useful in the treatment of alzheimer's disease and formulations containing the same

Country Status (16)

Country Link
US (1) US20070010507A1 (en)
EP (1) EP1638914A2 (en)
JP (1) JP2007505152A (en)
KR (1) KR20060012316A (en)
CN (1) CN1795158A (en)
AU (1) AU2004242838A1 (en)
BR (1) BRPI0410703A (en)
CA (1) CA2527354A1 (en)
DE (1) DE602004010100T2 (en)
EC (1) ECSP056190A (en)
IL (1) IL172213A0 (en)
IT (1) ITMI20031098A1 (en)
MX (1) MXPA05012826A (en)
NO (1) NO20056042L (en)
RU (1) RU2005136984A (en)
WO (1) WO2004106275A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060287554A1 (en) * 2005-06-21 2006-12-21 Madsen Kevin K Process for producing inorganic salts of hop acids
US20070104771A1 (en) * 2005-09-23 2007-05-10 Jay Audett Transdermal galantamine delivery system
EP2236160A3 (en) * 2009-03-31 2011-12-14 Sanovel Ilac Sanayi ve Ticaret A.S. Modified release dimebolin formulations
CA2776498A1 (en) * 2009-10-02 2011-04-07 Blanchette Rockefeller Neurosciences Institute Abnormal alterations of pkc isozymes processing in alzheimer's disease peripheral cells
DE102010024105A1 (en) 2010-06-17 2011-12-22 Grünenthal GmbH Transdermal administration of memantine
EP3328374A4 (en) * 2015-07-31 2019-03-13 The Johns Hopkins University Glutamine antagonists for the treatment of cognitive deficits

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999041220A1 (en) * 1998-02-13 1999-08-19 Dr. Willmar Schwabe Gmbh & Co. Stable hyperforin salts, method for producing same and their use in the treatment of alzheimer's disease
WO2000054785A2 (en) * 1999-03-15 2000-09-21 Shaman Pharmaceuticals, Inc. Stabilized bicyclo[3.3.1]nonenes and methods of use
EP2253314A3 (en) * 2001-10-26 2012-08-01 Metaproteomics, LLC Curcuminoid compositions exhibiting synergistic inhibition of the expression and/or activity of cyclooxygenase-2

Also Published As

Publication number Publication date
WO2004106275A2 (en) 2004-12-09
CN1795158A (en) 2006-06-28
ECSP056190A (en) 2006-08-30
MXPA05012826A (en) 2006-02-13
AU2004242838A1 (en) 2004-12-09
DE602004010100T2 (en) 2008-09-18
WO2004106275A3 (en) 2005-03-17
DE602004010100D1 (en) 2007-12-27
RU2005136984A (en) 2006-03-27
US20070010507A1 (en) 2007-01-11
ITMI20031098A0 (en) 2003-05-30
IL172213A0 (en) 2009-02-11
KR20060012316A (en) 2006-02-07
ITMI20031098A1 (en) 2004-11-30
JP2007505152A (en) 2007-03-08
NO20056042L (en) 2005-12-19
CA2527354A1 (en) 2004-12-09
EP1638914A2 (en) 2006-03-29

Similar Documents

Publication Publication Date Title
BR122019010200B8 (en) pyrazole-quinazoline compounds, their salts, products or kits and pharmaceutical compositions
DE60228857D1 (en) AMINO PHTALAZINONE DERIVATIVES, USE AS KINASE INHIBITORS, PREPARATION AND PHARMACEUTICAL COMPOSITION
BR0308196A (en) Compound, pharmaceutical formulation, use of a compound, methods for preventing and / or treating conditions associated with glycogen synthase kinase-3, and disease, and process for preparing a compound
BRPI0416656A (en) pyrrolopyrimidine compounds useful in cancer treatment
BR0317524A (en) Pyrrolopyrimidine derivatives, pharmaceutical composition, process for their preparation and their use
BRPI0408990A (en) pyrimidin-4-one derivatives and their use as p38 kinase modulators
BRPI0513819A (en) hsp90 inhibitors
BRPI0411863A (en) pyrazolyl indole derivatives as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
NO20093464L (en) New drug mixtures based on anti-cholinergically effective compounds and beta-mimetics
BRPI0411868B8 (en) pyrrole[3,4-c]pyrazole derivatives active as kinase inhibitors
BRPI0411255A (en) compound, pharmaceutical composition, use of a compound, methods of treating a disorder of a patient, and process for the preparation of a compound
BR0009043A (en) Compound, pharmaceutical composition, and method of treating a disease in an animal in which the activity of the cysteine protease contributes to the pathology and / or symptomatology of the disease
BRPI0514035A (en) compound, pharmaceutically acceptable salts thereof, diastereomers, enantiomers or mixtures thereof, use of a compound, pharmaceutical composition, method for the therapy of depression in a warm-blooded animal, and process for preparing a compound
BR0209658A (en) 4-Amino-5-phenyl-7-1-cyclobutyl-pyrrolo [2,3-d] pyrimidine derivatives
BR0307819A (en) Tricyclic pyrazole derivatives, process for preparing them as antitumor agents
BRPI0516093A (en) quinazoline derivative, process for preparing it, pharmaceutical composition, use of a quinazoline derivative, and method for treating cell proliferative disorders in a warm-blooded animal
EA200700362A1 (en) CONJUGAT, CONTAINING ANTI-VIRUS COMPOUND, IN PARTICULAR INHIBITING HIV, PHARMACEUTICAL COMPOSITION AND SET OF STANDARD DOSE OF THE MEDICINAL DRUG ON ITS BASIS, METHOD OF INHIBITING THE SOFTWARE PRO.
BRPI0512796A (en) compound, process for preparing same, pharmaceutical composition, use of a compound, and methods for producing an inhibitory effect of b-raf, and an anticancer effect on a warm-blooded animal, and for treating a disease.
BR0315988A (en) Amino-substituted dihydropyrimidate [4,5-d] pyrimidinone derivatives, their production and use as pharmaceutical agents
BRPI0512075A (en) compound, process for the preparation thereof, pharmaceutical composition, use of a compound, and methods for producing a b-raf inhibiting effect, and an anticancer effect on a warm-blooded animal, and for treating a disease
ATE355374T1 (en) THERAPEUTIC AGENTS AND METHODS OF THEIR USE FOR THE TREATMENT OF AMYLOIDOGENIC DISEASES
BR0211742A (en) Active Aminoisoxazole Derivatives as Kinase Inhibitors
BRPI0410316A (en) compound, pharmaceutical composition, use of the compounds, and method of treating vr1-mediated disorders and for the treatment of pain disorders
BRPI0416989A (en) aminopyrazole derivatives as gsk-3 inhibitors
BRPI0507375A (en) 1h-thieno [2,3-c] pyrazole derivatives useful as kinase inhibitors

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 5A, 6A, 7A E 8A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2159 DE 22/05/2012.